Why the study?
Does inhibition of delta-6 desaturase prevent contractile dysfunction and cardiolipin remodeling in aged (25 months) C57Bl/6 mice?
Does inhibition of delta-6 desaturase prevent contractile dysfunction and cardiolipin remodeling in aged (25 months) C57Bl/6 mice?
Inhibition of delta-6 desaturase in aged mice attenuates cardiac dilatation and contractile dysfunction by reversing PUFA redistribution, independent of mitochondrial respiratory function.
Does not yet support clinical use; leaves open translation of delta-6 desaturase inhibition to human age-related cardiac dysfunction.
Aging results in a redistribution of polyunsaturated fatty acids (PUFAs) in myocardial phospholipids. In particular, a selective loss of linoleic acid (18:2n6) with reciprocal increases of long-chain PUFAs (eg, arachidonic and docosahexaenoic acids) in the mitochondrial phospholipid cardiolipin correlates with cardiac mitochondrial dysfunction and contractile impairment in aging and related pathologies. In this study, we demonstrate a reversal of this aged-related PUFA redistribution pattern in cardiac mitochondria from aged (25 months) C57Bl/6 mice by inhibition of delta-6 desaturase, the rate limiting enzyme in long-chain PUFA biosynthesis. Interestingly, delta-6 desaturase inhibition had no effect on age-related mitochondrial respiratory dysfunction, H2O2 release, or lipid peroxidation but markedly attenuated cardiac dilatation, hypertrophy, and contractile dysfunction in aged mice. Taken together, our studies indicate that PUFA metabolism strongly influences phospholipid remodeling and cardiac function but dissociates these processes from mitochondrial respiratory dysfunction and oxidant production in the aged mouse heart.
No takes yet. Share an insight, caveat, or question.
Mulligan et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: